Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Leeuwenburgh

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
European Journal of Gastroenterology & Hepatology|November 3, 2001
Recovery of chronic hepatitis by treatment of concomitant hyperthyroidismI Leeuwenburgh, P J Stijnen, G P Verburg
Alimentary Pharmacology & Therapeutics|June 18, 2011
Practice patterns for achalasia--room for improvement?I Leeuwenburgh, J Alderliesten, A C De Vries, et al.
Gut|November 12, 2010
Predictors for outcome of failure of balloon dilatation in patients with achalasiaJ Alderliesten, J M Conchillo, I Leeuwenburgh, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 7, 2019
Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma?K Nesteruk, M C W Spaander, I Leeuwenburgh, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 1, 2002
[Melioidosis]I Leeuwenburgh, J T N Driessen, P H J van Keulen, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Oesophagitis is common in patients with achalasia after pneumatic dilatationI Leeuwenburgh, H Van Dekken, P Scholten, et al.
The American Journal of Gastroenterology|July 1, 2010
Long-term esophageal cancer risk in patients with primary achalasia: a prospective studyI Leeuwenburgh, P Scholten, J Alderliesten, et al.
Digestive Diseases and Sciences|November 27, 2012
Barrett's esophagus and esophageal adenocarcinoma are common after treatment for achalasiaI Leeuwenburgh, P Scholten, T J Caljé, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|February 2, 2010
Expression of p53 as predictor for the development of esophageal cancer in achalasia patientsI Leeuwenburgh, M M Gerrits, A Capello, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2008
Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adductsP J F De Jonge, P D Siersema, S G J Van Breda, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Journal of Gastroenterology & Hepatology|November 3, 2001
Recovery of chronic hepatitis by treatment of concomitant hyperthyroidismI Leeuwenburgh, P J Stijnen, G P Verburg
Alimentary Pharmacology & Therapeutics|June 18, 2011
Practice patterns for achalasia--room for improvement?I Leeuwenburgh, J Alderliesten, A C De Vries, et al.
Gut|November 12, 2010
Predictors for outcome of failure of balloon dilatation in patients with achalasiaJ Alderliesten, J M Conchillo, I Leeuwenburgh, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|May 7, 2019
Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma?K Nesteruk, M C W Spaander, I Leeuwenburgh, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 1, 2002
[Melioidosis]I Leeuwenburgh, J T N Driessen, P H J van Keulen, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2006
Oesophagitis is common in patients with achalasia after pneumatic dilatationI Leeuwenburgh, H Van Dekken, P Scholten, et al.
The American Journal of Gastroenterology|July 1, 2010
Long-term esophageal cancer risk in patients with primary achalasia: a prospective studyI Leeuwenburgh, P Scholten, J Alderliesten, et al.
Digestive Diseases and Sciences|November 27, 2012
Barrett's esophagus and esophageal adenocarcinoma are common after treatment for achalasiaI Leeuwenburgh, P Scholten, T J Caljé, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|February 2, 2010
Expression of p53 as predictor for the development of esophageal cancer in achalasia patientsI Leeuwenburgh, M M Gerrits, A Capello, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2008
Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adductsP J F De Jonge, P D Siersema, S G J Van Breda, et al.
Pageof 2